REPORT FROM ARGENTINA OF FIRST THREE YEARS FOLLOWS UP OF AUTOLOGOUS STEM CELLS IMPLANT IN DIABETES TYPE 1 (WORLD WIDE PIONEER EXPERIENCE )

REPORT FROM ARGENTINA OF FIRST THREE YEARS FOLLOWS UP OF AUTOLOGOUS STEM CELLS IMPLANT IN DIABETES TYPE 1 (WORLD WIDE PIONEER EXPERIENCE )
Author Block Fernandez Vina, Roberto Fernandez Vina Foundation Argentina, Buenos Aires, Argentina Abstract: Background: The adults stem cells CD34 (+)CD38(-) have the capacity to differentiate in functional cells on endocrine pancreas We did the first implant of ASC in the world in diabetes 1 in 2005 . Objectives: To report the long time performance of Diabetic type 1 patients treated with Stems cells implant. Method: Following first three year on cell therapy for diabetes 1 the conclusions are optimistic. In this study were observed the evolution of 38 Diabetic type 1 patients, 20 male, 18 female, average age 23.06 years old (±20.2). All the patients were under insulin therapy. For the transplantation were harvest bone marrow from iliac crest by aspiration, following the sample was processed using a density gradient separation method, obtained 120ml (±95) of CD34(+)CD38(-) solution. For the implant was procedure a catheterization through Spleen Artery. No complications or further events were observed during or after the procedure. The patients were subjected to clinical and blood samples control during the 12 months following the implant. C-Peptide Basal (ng/ml), Basal 0.39, 6 Months 0.54, 36 Months 1.95, Increment 98.30%, C-Peptide after meal (ng/ml), Basal 0.46, 6 Months 0.56 36 Months 2.54, increment 151.63%, H1c Basal 8.4, 6 Months 7.39.36 Months 6,54, Decrement 24,58%, Insulin Basal (MU/ml), Basal 5.09, 6 M onths 12,25, 36 Months18.66,Increment23,25%, Insulin Doses (IU/day): Basal, 54,96, 6 Months 35,83,36 Months 12,60, Decrement 65,44%
Conclusions:
The implant of mononuclear CD34+CD38- ( stem cells) from autologous bone marrow improve pancreatic function in patients with type 1 diabetes, in a safety form and is maintained after 3 years at least